Shenzhen Neptunus Interlong Bio-technique Company Limited released its 10th Environmental, Social and Governance (ESG) Report, covering the period from 1 January 2025 to 31 December 2025 for the parent firm and six key subsidiaries in Shenzhen, Fuzhou, Beijing and Hainan.
Key governance upgrades • The board retains full oversight of ESG strategy, supported by a chairman-led ESG Leading Team and subsidiary-level ESG Working Teams. • Annual reviews, materiality assessments and third-party data verifications underpin report preparation in line with HKEx Appendix C2 requirements.
Environmental performance • Total greenhouse-gas emissions fell 9.41 % year-on-year to 11,242 tCO₂e, driven by a 17.31 % cut in Scope 1 emissions as natural-gas and fuel consumption declined. • Wastewater discharge edged down 1.10 % to 100,354 t, though chemical-oxygen demand rose 34.07 % to 3,793 kg due to increased cleaning cycles during product line changes. • Hazardous waste generation dropped 10.78 % to 79.57 t, while non-hazardous waste declined 10.41 % to 482 t. • Group energy intensity improved 6.65 % to 36.86 MWh per million renminbi of revenue; water intensity fell 3.22 % to 326.24 t per million renminbi. • Targets include further reductions in exhaust-gas concentrations and continued optimisation of water use through equipment upgrades and recycling initiatives.
Operational highlights • Fuzhou Production Base completed a major upgrade of its second glass-bottle injection line and passed GMP compliance, enhancing capacity for 100 ml products while saving electricity and an estimated 1,500 t of cooling water annually. • Beijing Production Base saw three production lines in Workshop 101 secure GMP compliance and recommenced operations.
Product responsibility and quality • No product recalls were recorded; 21 customer complaints were all resolved under established quality-complaint procedures. • Five generic drugs have passed consistency evaluations, and additional new drug approvals were obtained, including Doxofylline Injection and Sildenafil Citrate Orodispersible Tablets. • Company-wide pharmacovigilance, traceability and recall systems remain in place, supported by annual quality audits and staff training.
Workforce and safety • Total headcount stood at 1,382 (41 % men, 59 % women); staff turnover was 21.83 %, broadly unchanged year-on-year. • Over 87 % of employees received training, averaging 29.49 hours per person. • Two work-related injuries were reported, with zero fatalities; 89 lost workdays were recorded. • Regular fire-safety, hazardous-waste and emergency-response drills were conducted across production sites.
Supply-chain and compliance • The Group engaged 465 domestic suppliers in 2025, up from 435 a year earlier, under a strengthened audit and quality-assessment framework. • All new suppliers undergo stringent GMP/GSP qualification reviews, and ongoing performance audits are conducted to mitigate operational and ESG risks. • No corruption cases were reported; all staff completed integrity and anti-bribery training.
Community engagement • Employees participated in blood-donation drives and local volunteer programmes, reinforcing corporate citizenship commitments.
Neptunus Interlong’s board approved the ESG Report on 24 April 2026, reaffirming the company’s commitment to integrating sustainability, regulatory compliance and product excellence into its long-term growth strategy.
Comments